For Media Inquiries, Please Contact:
4100 Weston Road,
ON, M9L 1P9
Jun 12, 2017Apobiologix, a division of the Apotex Group focused on biologics innovation, today announced their support of the Supreme Court decision in the Sandoz v Amgen case. The case clarifies the timing of the Biologics Price Competition and Innovation Act (BPCIA) requiring biosimilar companies to provide 180-days notice to the companies of the reference products of intent to market the biosimilar.
Jun 8, 2017Two Toronto scientists who spearheaded the research that brought a life-saving drug to patients around the world are being honored at the annual Cooley's Anemia Foundation Gala tonight in New York City.
Apr 28, 2017University of Saskatchewan, Apotex renew partnership with $1.6M donation to the College of Pharmacy and NutritionThe University of Saskatchewan and Apotex Inc. have renewed their partnership with a $1.6 million donation by the company to the College of Pharmacy and Nutrition.
Mar 8, 2017Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence; Expansion Plan Comprises Company's Largest Investment in the United StatesToday Apotex Inc., the largest Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan
Mar 31, 2016Apobiologix®, a Division of Apotex Inc., today launched Grastofil®, its first subsequent entry biologic (SEB) approved in Canada.
Mar 24, 2016Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.